Comparison of posaconazole and voriconazole in vitro killing against Candida krusei

Diagnostic Microbiology and Infectious Disease

Volumn 62, Issue 2, 2008, Pages 177-181

  Cantón, Emilia ^a   Pemán, Javier ^a   Valentín, Amparo ^a   Bosch, Maria ^a   Espinel Ingroff, Ana ^b   Gobernado, Miguel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Candida krusei; MFC; MIC; Posaconazole; Time killing; Voriconazole

Indexed keywords

AGAR; GLUCOSE; POSACONAZOLE; VORICONAZOLE;

ARTICLE; CANDIDA KRUSEI; CONTROLLED STUDY; CULTURE MEDIUM; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; GEOMETRY; HUMAN; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CULTURE MEDIA; DRUG RESISTANCE, FUNGAL; FUNGEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TIME FACTORS; TRIAZOLES;

EID: 51649102488     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.07.001     Document Type: Article

References (20)

1. Bopp L.H., Baltch A.L., Ritz W.J., Michelsen P.B., and Smith R.P. Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages. J. Med. Microbiol. 55 (2006) 865-870
2. Cantón E., Pemán J., Viudes A Quindós G., Gobernado M., and Espinel-Ingroff A. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn. Microbiol. Infect. Dis. 45 (2003) 203-206
3. Cantón E., Pemán J., Gobernado M., Viudes A., and Espinel-Ingroff A. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob. Agents Chemother. 48 (2004) 2477-2482
4. Cantón E., Pemán J., Espinel-Ingroff A., Martín-Mazuelos E., Carrillo-Muñoz A., and Martínez J.P. Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts. J. Antimicrob. Chemother. 61 (2008) 135-138
5. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement. CLSI Document M27-S3 (2008), Clinical and Laboratory Standards Institute, Wayne, PA
6. Ernst E.J., Yodoi K., Roling E.E., and Klepser M.E. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob. Agents. Chemother. 46 (2002) 578-581
7. Girmenia C., Moleti M.L., Micozzi A., Iori A.P., Barberi W., Foà R., and Martino P. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J. Clin. Microbiol. 43 (2005) 5395-5396
8. Klepser M.E., Malone D., Lewis R.E., Ernst E.J., and Pfaller M.A. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob. Agents and Chemother. 44 (2000) 1917-1920
9. Muñoz P., Sánchez-Somolinos M., Alcalá L., Rodríguez-Créixems M., Peláez T., and Bouza E. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J. Antimicrob. Chemother. 55 (2005) 188-193
10. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard-second edition. CLSI document M27-A2 (2002), Clinical and Laboratory Standards Institute, Wayne, PA
11. Pemán J., Cantón E., Orero A., Viudes A., Frasquet J., and Gobernado M. Estudio multicéntrico sobre la epidemiología de las candidemias en España. Rev. Iberoam. Micol. 19 (2002) 30-35
12. Pemán J., Cantón E., and Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 24 (2005) 23-30
13. Pemán J., Cantón E., Calabuig E., Bosch M., Valentin A., Viudes A., and Gobernado M. Actividad in vitro de voriconazol frente a levaduras y algas con los nuevos puntos de corte del patrón de resistencia. Rev. Esp. Quimioter. 19 (2006) 21-33
14. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Nagy E., Doviasoba S., Rinaldi M., Barton R., Veselov A., and and the Global Antifungal Surveillance Group. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46 (2008) 515-521
15. Rubio M.C., de Ocáriz I.R., Gil J., Benito R., and Rezusta A. Potential fungicidal effect of voriconazole against Candida spp. Int. J. Antimicrob. Agents. 25 (2005) 264-267
16. Sabatelli F., Patel R., Mann P.A., Mendrick C.A., Norris C.C., Hare R., Loebenberg D., Black T.A., and McNicholas P.M. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50 (2006) 2009-2015
17. Sandven P. Epidemiology of candidemia. Rev. Iberoam. Micol. 17 (2000) 73-81
18. Sóczó G., Kardos G., McNicholas P.M., Balogh E., Gergely L., Varga I., Kelentey B., and Majoros L. Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species. J Antimicrob Chemother 60 (2007) 1004-1009
19. Viudes A., Pemán J., Cantón E., Úbeda P., López-Ribot J.L., and Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur. J. Clin. Microbiol. Infect. Dis. 21 (2002) 767-774
20. Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., and Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325 (1991) 1274-1277